Benjamin Rome: key facts
- Kind of voice
- Academic
- Role
- Harvard healthy policy researcher
- Quoted on
- Rare diseases
- Press citations held
- 2
- Most recently quoted
- 30 Sept 2026
“Even a one-year delay in negotiating the prices for those drugs will be extraordinarily consequential”
What Benjamin Rome has said
“Harvard Medical School researchers Benjamin Rome and Aaron Kesselheim, who have published repeatedly on this question, have argued that expanding the exemption would unnecessarily limit the number of eligible drugs while allowing continued high prices for products earning billions in Medicare.”
Harvard Medical School researcher · Rare diseases · 30 Sept 2026 · Exempting Rare Disease Drugs Would Erase Most Savings from a Medicare Price Pilot, Analysis Finds ↗
Where Benjamin Rome has been quoted
- CMS Finalizes Stronger Protections for Orphan Drugs Against IRA Price Negotiationsbiospace.com · 30 Sept 2026
- Exempting Rare Disease Drugs Would Erase Most Savings from a Medicare Price Pilot, Analysis Findsmedicaldaily.com · 30 Sept 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 30 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.